Q3 2020 13F Holders as of 9/30/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
61.4M
-
Number of holders
-
91
-
Total 13F shares, excl. options
-
37.2M
-
Shares change
-
+3.12M
-
Total reported value, excl. options
-
$727M
-
Value change
-
+$62.1M
-
Number of buys
-
47
-
Number of sells
-
-44
-
Price
-
$19.55
Significant Holders of Protagonist Therapeutics, Inc - Common Stock (PTGX) as of Q3 2020
103 filings reported holding PTGX - Protagonist Therapeutics, Inc - Common Stock as of Q3 2020.
Protagonist Therapeutics, Inc - Common Stock (PTGX) has 91 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 37.2M shares
of 61.4M outstanding shares and own 60.56% of the company stock.
Largest 10 shareholders include FMR LLC (5.2M shares), RTW INVESTMENTS, LP (3.41M shares), FARALLON CAPITAL MANAGEMENT LLC (2.75M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.52M shares), BlackRock Inc. (2.46M shares), Johnson & Johnson Innovation - JJDC, Inc. (2.45M shares), BVF INC/IL (2.37M shares), Consonance Capital Management LP (2.37M shares), BAKER BROS. ADVISORS LP (1.6M shares), and VANGUARD GROUP INC (1.55M shares).
This table shows the top 91 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.